Mustang Bio Inc (MBIO) USD0.0001
$0.0031
(1.89%)
- Add to watchlist
- This stock can be held in a
$0.0031
(1.89%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.0031
(1.89%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. It is developing a CAR T therapy for hematologic malignancies in partnership with Fred Hutch targeting CD20 (MB-106). In partnership with St. Jude, its X-linked Severe Combined Immunodeficiency (XSCID) gene therapy programs (MB-117 and MB-217) are being developed under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition.
Contact details
Important dates
General stock information
- Short code:
- MBIO
- ISIN:
- US62818Q2030
- Market cap:
- $8.29 million
- Shares in issue:
- 49.61 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.